TY - JOUR T1 - Profile of SARS-CoV-2-specific CD4 T cell response: Relationship with disease severity and impact of HIV-1 and active <em>Mycobacterium tuberculosis</em> co-infection JF - medRxiv DO - 10.1101/2021.02.16.21251838 SP - 2021.02.16.21251838 AU - Catherine Riou AU - Elsa du Bruyn AU - Cari Stek AU - Remy Daroowala AU - Rene T. Goliath AU - Fatima Abrahams AU - Qonita Said-Hartley AU - Brian W. Allwood AU - Marvin Hsiao AU - Katalin A. Wilkinson AU - Cecilia S. Lindestam Arlehamn AU - Alessandro Sette AU - Sean Wasserman AU - Robert J. Wilkinson AU - on behalf of the HIATUS consortium Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/02/20/2021.02.16.21251838.abstract N2 - T cells are involved in control of COVID-19, but limited knowledge is available on the relationship between antigen-specific T cell response and disease severity. Here, we assessed the magnitude, function and phenotype of SARS-CoV-2-specific CD4 T cells in 95 hospitalized COVID-19 patients (38 of them being HIV-1 and/or tuberculosis (TB) co-infected) and 38 non-COVID-19 patients, using flow cytometry. We showed that SARS-CoV-2-specific CD4 T cell attributes, rather than magnitude, associates with disease severity, with severe disease being characterized by poor polyfunctional potential, reduced proliferation capacity and enhanced HLA-DR expression. Moreover, HIV-1 and TB co-infection skewed the SARS-CoV-2 T cell response. HIV-1 mediated CD4 T cell depletion associated with suboptimal T cell and humoral immune responses to SARS-CoV-2; and a decrease in the polyfunctional capacity of SARS-CoV-2-specific CD4 T cells was observed in COVID-19 patients with active TB. Our results also revealed that COVID-19 patients displayed reduced frequency of Mtb-specific CD4 T cells, with possible implications for TB disease progression. There results corroborate the important role of SARS-CoV-2-specific T cells in COVID-19 pathogenesis and support the concept of altered T cell functions in patients with severe disease.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by Wellcome Trust (104803, 203135 to RJW) and the National Institutes of Health (NIH) (R21AI148027 to CR). CR is supported by the European and Developing Countries Clinical Trials Partnership EDCTP2 programme supported by the European Union (EU) Horizon 2020 programme (Training and Mobility Action TMA2017SF-1951-TB-SPEC to CR). EdB is supported by a Harry Crossley Senior Clinical Fellowship. The authors declare no conflict of interest.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:University of Cape Town IRBAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThis study did not generate any unique datasets or code. ER -